{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:03:19Z","timestamp":1792843399596,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56 AI118756"],"award-info":[{"award-number":["R56 AI118756"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","award":["TEF-IT-54"],"award-info":[{"award-number":["TEF-IT-54"]}],"id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic airways infection with methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) is associated with worse respiratory disease cystic fibrosis (CF) patients. Ceftaroline is\u00a0a cephalosporin that inhibits the penicillin-binding protein (PBP2a) uniquely produced by MRSA. We analyzed 335 <jats:italic>S. aureus<\/jats:italic> isolates from CF sputum samples collected at three US centers between 2015\u20132018. Molecular relationships demonstrated that high-level resistance of preceding isolates to carbapenems were associated with subsequent isolation of ceftaroline resistant CF MRSA. In vitro evolution experiments showed that pre-exposure of CF MRSA to meropenem with further selection with ceftaroline implied mutations in <jats:italic>mecA<\/jats:italic> and additional mutations in <jats:italic>pbp1<\/jats:italic> and <jats:italic>pbp2<\/jats:italic>, targets of carbapenems; no effects were achieved by other \u03b2-lactams. An in vivo pneumonia mouse model showed the potential therapeutic efficacy of ceftaroline\/meropenem combination against ceftaroline-resistant CF MRSA infections. Thus, the present findings highlight risk factors and potential therapeutic strategies offering an opportunity to both prevent and address antibiotic resistance in this patient population.<\/jats:p>","DOI":"10.1038\/s42003-020-01313-5","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:03:14Z","timestamp":1603360994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA"],"prefix":"10.1038","volume":"3","author":[{"given":"Maria Celeste","family":"Varela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Taglialegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-5307","authenticated-orcid":false,"given":"Scott W.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Ojeda","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren E.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4408-7411","authenticated-orcid":false,"given":"Rafael E.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto R.","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana E.","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"1313_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1542\/pir.35-5-194","volume":"35","author":"SM Paranjape","year":"2014","unstructured":"Paranjape, S. M. & Mogayzel, P. J. Jr. Cystic fibrosis. Pediatr. Rev. 35, 194\u2013205 (2014).","journal-title":"Pediatr. Rev."},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","volume":"11","author":"PJ Mogayzel Jr","year":"2014","unstructured":"Mogayzel, P. J. Jr et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 11, 1640\u20131650 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1313_CR3","unstructured":"Foundation, C. F. Cystic Fibrosis Foundation Patient Registry. 2018 Annual Data Report. (Bethesda, Maryland, 2019)."},{"key":"1313_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp, E. A. et al. The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry. Ann. Am. Thorac. Soc. 13, 1173\u20131179 (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1313_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1378\/chest.15-0676","volume":"149","author":"EL Salsgiver","year":"2016","unstructured":"Salsgiver, E. L. et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 149, 390\u2013400 (2016).","journal-title":"Chest"},{"key":"1313_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.pcl.2016.04.003","volume":"63","author":"ET Zemanick","year":"2016","unstructured":"Zemanick, E. T. & Hoffman, L. R. Cystic fibrosis: microbiology and host response. Pediatr. Clin. North Am. 63, 617\u2013636 (2016).","journal-title":"Pediatr. Clin. North Am."},{"key":"1313_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/JCM.01510-06","volume":"45","author":"S Besier","year":"2007","unstructured":"Besier, S. et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45, 168\u2013172 (2007).","journal-title":"J. Clin. Microbiol."},{"key":"1313_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","volume":"182","author":"DB Sanders","year":"2010","unstructured":"Sanders, D. B. et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 182, 627\u2013632 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1313_CR9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MCP.0b013e32834b95ed","volume":"17","author":"EC Dasenbrook","year":"2011","unstructured":"Dasenbrook, E. C. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr. Opin. Pulm. Med. 17, 437\u2013441 (2011).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ppul.24537","volume":"55","author":"QJ Epps","year":"2020","unstructured":"Epps, Q. J., Epps, K. L., Young, D. C. & Zobell, J. T. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. Pediatr. Pulmonol. 55, 33\u201357 (2020).","journal-title":"Pediatr. Pulmonol."},{"key":"1313_CR11","doi-asserted-by":"publisher","first-page":"16808","DOI":"10.1073\/pnas.1300118110","volume":"110","author":"LH Otero","year":"2013","unstructured":"Otero, L. H. et al. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl Acad. Sci. USA 110, 16808\u201316813 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1313_CR12","doi-asserted-by":"crossref","unstructured":"Casapao, A. M. et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob. Agents Chemother. 57, 4252\u20134259 (2013).","DOI":"10.1128\/AAC.00380-13"},{"key":"1313_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-018-0905-x","volume":"19","author":"G Sotgiu","year":"2018","unstructured":"Sotgiu, G. et al. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respir. Res. 19, 205 (2018).","journal-title":"Respir. Res."},{"issue":"Suppl 4","key":"1313_CR14","first-page":"iv17","volume":"65","author":"RN Jones","year":"2010","unstructured":"Jones, R. N., Mendes, R. E. & Sader, H. S. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65(Suppl 4), iv17\u2013iv31 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR15","doi-asserted-by":"crossref","unstructured":"Sader, H. S., Rhomberg, P. R., Doyle, T. B., Flamm, R. K. & Mendes, R. E. Evaluation of the revised ceftaroline disk diffusion breakpoints when testing a challenge collection of methicillin-resistant Staphylococcus aureus isolates. J. Clin. Microbiol. 56, e00777-18 (2018).","DOI":"10.1128\/JCM.00777-18"},{"key":"1313_CR16","unstructured":"Clinical and Laboratory Standards Institute (CLSI). M100 Performance Standards for Antimicrobial Susceptibility Testing (Wayne, PA, 2018)."},{"key":"1313_CR17","unstructured":"Clinical and Laboratory Standards Institute\/National Committee for Clinical Laboratory Standards (NCCLS). M100-S25: Performance Standards for Antimicrobial Susceptibility Testing (Villanova, PA, 2015)."},{"key":"1313_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/INF.0000000000001171","volume":"35","author":"CR Cannavino","year":"2016","unstructured":"Cannavino, C. R. et al. Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. Pediatr. Infect. Dis. J. 35, 813\u2013815 (2016).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1313_CR19","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1128\/AAC.03622-14","volume":"58","author":"SW Long","year":"2014","unstructured":"Long, S. W. et al. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 58, 6668\u20136674 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR20","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1128\/AAC.03019-14","volume":"58","author":"R Fernandez","year":"2014","unstructured":"Fernandez, R., Paz, L. I., Rosato, R. R. & Rosato, A. E. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance. Antimicrob. Agents Chemother. 58, 5736\u20135746 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/jac\/dks069","volume":"67","author":"RE Mendes","year":"2012","unstructured":"Mendes, R. E. et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J. Antimicrob. Chemother. 67, 1321\u20131324 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR22","doi-asserted-by":"crossref","unstructured":"Alm, R. A. et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J. Antimicrob. Chemother. 69, 2065\u20132075 (2014).","DOI":"10.1093\/jac\/dku114"},{"key":"1313_CR23","doi-asserted-by":"publisher","first-page":"e0125864","DOI":"10.1371\/journal.pone.0125864","volume":"10","author":"B Strommenger","year":"2015","unstructured":"Strommenger, B., Layer, F., Klare, I. & Werner, G. Pre-use susceptibility to ceftaroline in Clinical Staphylococcus aureus isolates from Germany: is there a non-susceptible pool to be selected? PLoS ONE 10, e0125864 (2015).","journal-title":"PLoS ONE"},{"key":"1313_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jac\/dkv325","volume":"71","author":"F Schaumburg","year":"2016","unstructured":"Schaumburg, F., Peters, G., Alabi, A., Becker, K. & Idelevich, E. A. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J. Antimicrob. Chemother. 71, 41\u201344 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR25","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1128\/AAC.04068-14","volume":"59","author":"WL Kelley","year":"2015","unstructured":"Kelley, W. L., Jousselin, A., Barras, C., Lelong, E. & Renzoni, A. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Antimicrob. Agents Chemother. 59, 1922\u20131930 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.diagmicrobio.2012.08.022","volume":"75","author":"RN Jones","year":"2013","unstructured":"Jones, R. N., Flamm, R. K., Sader, H. S. & Stilwell, M. G. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate beta-lactam markers to predict ceftaroline activity against clinically indicated species. Diagn. Microbiol. Infect. Dis. 75, 89\u201393 (2013).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/bib\/bbx083","volume":"20","author":"DA Antonopoulos","year":"2019","unstructured":"Antonopoulos, D. A. et al. PATRIC as a unique resource for studying antimicrobial resistance. Brief. Bioinform 20, 1094\u20131102 (2019).","journal-title":"Brief. Bioinform"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1365-2958.2004.04420.x","volume":"55","author":"MG Pinho","year":"2005","unstructured":"Pinho, M. G. & Errington, J. Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates. Mol. Microbiol. 55, 799\u2013807 (2005).","journal-title":"Mol. Microbiol."},{"key":"1313_CR29","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1128\/JB.183.22.6525-6531.2001","volume":"183","author":"MG Pinho","year":"2001","unstructured":"Pinho, M. G., Filipe, S. R., de Lencastre, H. & Tomasz, A. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J. Bacteriol. 183, 6525\u20136531 (2001).","journal-title":"J. Bacteriol."},{"key":"1313_CR30","doi-asserted-by":"publisher","first-page":"e1004891","DOI":"10.1371\/journal.ppat.1004891","volume":"11","author":"P Reed","year":"2015","unstructured":"Reed, P. et al. Staphylococcus aureus survives with a minimal peptidoglycan synthesis machine but sacrifices virulence and antibiotic resistance. PLoS. Pathog. 11, e1004891 (2015).","journal-title":"PLoS. Pathog."},{"key":"1313_CR31","doi-asserted-by":"crossref","unstructured":"Karinou, E., Schuster, C. F., Pazos, M., Vollmer, W. & Grundling, A. Inactivation of the monofunctional peptidoglycan glycosyltransferase SgtB allows Staphylococcus aureus to survive in the absence of lipoteichoic acid. J. Bacteriol. 201, e00574-18 (2019).","DOI":"10.1128\/JB.00574-18"},{"key":"1313_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/45.4.421","volume":"45","author":"H Komatsuzawa","year":"2000","unstructured":"Komatsuzawa, H. et al. Tn551-mediated insertional inactivation of the fmtB gene encoding a cell wall-associated protein abolishes methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 45, 421\u2013431 (2000).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/infdis\/jis311","volume":"206","author":"A Garofalo","year":"2012","unstructured":"Garofalo, A. et al. The length of the Staphylococcus aureus protein A polymorphic region regulates inflammation: impact on acute and chronic infection. J. Infect. Dis. 206, 81\u201390 (2012).","journal-title":"J. Infect. Dis."},{"key":"1313_CR34","first-page":"126ra135","volume":"4","author":"CM Tan","year":"2012","unstructured":"Tan, C. M. et al. Restoring methicillin-resistant Staphylococcus aureus susceptibility to beta-lactam antibiotics. Sci. Transl. Med. 4, 126ra135 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1313_CR35","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1128\/AAC.01401-10","volume":"55","author":"O Dumitrescu","year":"2011","unstructured":"Dumitrescu, O. et al. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob. Agents Chemother. 55, 3261\u20133271 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR36","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1128\/AAC.00029-07","volume":"51","author":"TA Davies","year":"2007","unstructured":"Davies, T. A. et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51, 2621\u20132624 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR37","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1128\/JB.00044-07","volume":"189","author":"SF Pereira","year":"2007","unstructured":"Pereira, S. F., Henriques, A. O., Pinho, M. G., de Lencastre, H. & Tomasz, A. Role of PBP1 in cell division of Staphylococcus aureus. J. Bacteriol. 189, 3525\u20133531 (2007).","journal-title":"J. Bacteriol."},{"key":"1313_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2958.2009.06687.x","volume":"72","author":"SF Pereira","year":"2009","unstructured":"Pereira, S. F., Henriques, A. O., Pinho, M. G., de, L. H. & Tomasz, A. Evidence for a dual role of PBP1 in the cell division and cell separation of Staphylococcus aureus. Mol. Microbiol. 72, 895\u2013904 (2009).","journal-title":"Mol. Microbiol."},{"key":"1313_CR39","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1128\/JB.185.11.3446-3452.2003","volume":"185","author":"AE Rosato","year":"2003","unstructured":"Rosato, A. E., Craig, W. A. & Archer, G. L. Quantitation of mecA transcription in oxacillin-resistant Staphylococcus aureus clinical isolates. J. Bacteriol. 185, 3446\u20133452 (2003).","journal-title":"J. Bacteriol."},{"key":"1313_CR40","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1128\/AAC.47.4.1460-1463.2003","volume":"47","author":"AE Rosato","year":"2003","unstructured":"Rosato, A. E. et al. mecA-blaZ corepressors in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 47, 1460\u20131463 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR41","doi-asserted-by":"publisher","first-page":"e61083","DOI":"10.1371\/journal.pone.0061083","volume":"8","author":"KB Plata","year":"2013","unstructured":"Plata, K. B., Riosa, S., Singh, C. R., Rosato, R. R. & Rosato, A. E. Targeting of PBP1 by beta-lactams determines recA\/SOS response activation in heterogeneous MRSA clinical strains. PLoS ONE 8, e61083 (2013).","journal-title":"PLoS ONE"},{"key":"1313_CR42","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/jac\/dkr198","volume":"66","author":"AP Desbois","year":"2011","unstructured":"Desbois, A. P. & Coote, P. J. Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents. J. Antimicrob. Chemother. 66, 1785\u20131790 (2011).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR43","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fphar.2019.00849","volume":"10","author":"S Esposito","year":"2019","unstructured":"Esposito, S. et al. Antimicrobial treatment of Staphylococcus aureus in patients with cystic fibrosis. Front Pharm. 10, 849 (2019).","journal-title":"Front Pharm."},{"key":"1313_CR44","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1128\/AAC.01046-16","volume":"60","author":"MH Mustafa","year":"2016","unstructured":"Mustafa, M. H. et al. Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Northern Europe. Antimicrob. Agents Chemother. 60, 6735\u20136741 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijantimicag.2016.09.012","volume":"48","author":"H Chalhoub","year":"2016","unstructured":"Chalhoub, H. et al. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. Int J. Antimicrob. Agents 48, 740\u2013743 (2016).","journal-title":"Int J. Antimicrob. Agents"},{"key":"1313_CR46","first-page":"47","volume":"41","author":"E Delfino","year":"2018","unstructured":"Delfino, E. et al. Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series. N. Microbiol 41, 47\u201351 (2018).","journal-title":"N. Microbiol"},{"key":"1313_CR47","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2017.10.010","volume":"17","author":"EE Barsky","year":"2018","unstructured":"Barsky, E. E. et al. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J. Cyst. Fibros. 17, e25\u2013e31 (2018).","journal-title":"J. Cyst. Fibros."},{"key":"1313_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.diagmicrobio.2017.11.012","volume":"90","author":"N Suwantarat","year":"2018","unstructured":"Suwantarat, N. et al. Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 90, 296\u2013299 (2018).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"1313_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/phar.1681","volume":"36","author":"EB Autry","year":"2016","unstructured":"Autry, E. B. et al. Pharmacokinetic and pharmacodynamic analyses of ceftaroline in adults with cystic fibrosis. Pharmacotherapy 36, 13\u201318 (2016).","journal-title":"Pharmacotherapy"},{"key":"1313_CR50","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1093\/jac\/dkx214","volume":"72","author":"R Singh","year":"2017","unstructured":"Singh, R. et al. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. J. Antimicrob. Chemother. 72, 2796\u20132803 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"1313_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2014.11.016","volume":"81","author":"ME Stryjewski","year":"2015","unstructured":"Stryjewski, M. E., Jones, R. N. & Corey, G. R. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. Diagn. Microbiol. Infect. Dis. 81, 183\u2013188 (2015).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"1313_CR52","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1128\/AAC.01797-09","volume":"54","author":"MR Jacobs","year":"2010","unstructured":"Jacobs, M. R. et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54, 2716\u20132719 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","volume":"77","author":"HS Sader","year":"2018","unstructured":"Sader, H. S., Flamm, R. K., Streit, J. M., Carvalhaes, C. G. & Mendes, R. E. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. Int. J. Infect. Dis. 77, 82\u201386 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"1313_CR54","doi-asserted-by":"crossref","unstructured":"Pfaller, M. A., Mendes, R. E., Duncan, L. R., Flamm, R. K. & Sader, H. S. In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: results from seven years of the AWARE surveillance program (2010 to 2016). Antimicrob. Agents Chemother. 62, e01555-17 (2018).","DOI":"10.1128\/AAC.01555-17"},{"key":"1313_CR55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10096-016-2807-5","volume":"36","author":"DO Andrey","year":"2017","unstructured":"Andrey, D. O. et al. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013\u20132014 at the Geneva University Hospitals. Eur. J. Clin. Microbiol Infect. Dis. 36, 343\u2013350 (2017).","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"1313_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/AAC.36.3.552","volume":"36","author":"RH Barbhaiya","year":"1992","unstructured":"Barbhaiya, R. H. et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36, 552\u2013557 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1313_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jac\/dkt300","volume":"69","author":"JM Butterfield","year":"2014","unstructured":"Butterfield, J. M. et al. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin\/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J. Antimicrob. Chemother. 69, 176\u2013179 (2014).","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 1","key":"1313_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-S1-S7","volume":"14","author":"SI Nikolenko","year":"2013","unstructured":"Nikolenko, S. I., Korobeynikov, A. I. & Alekseyev, M. A. BayesHammer: Bayesian clustering for error correction in single-cell sequencing. BMC Genomics 14(Suppl 1), S7 (2013).","journal-title":"BMC Genomics"},{"key":"1313_CR59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cmb.2012.0021","volume":"19","author":"A Bankevich","year":"2012","unstructured":"Bankevich, A. et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 19, 455\u2013477 (2012).","journal-title":"J. Comput. Biol."},{"key":"1313_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/srep08365","volume":"5","author":"T Brettin","year":"2015","unstructured":"Brettin, T. et al. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci. Rep. 5, 8365 (2015).","journal-title":"Sci. Rep."},{"key":"1313_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-5-113","volume":"5","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinforma. 5, 113 (2004).","journal-title":"BMC Bioinforma."},{"key":"1313_CR62","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792\u20131797 (2004).","journal-title":"Nucleic Acids Res."},{"key":"1313_CR63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/10635150701472164","volume":"56","author":"G Talavera","year":"2007","unstructured":"Talavera, G. & Castresana, J. Improvement of phylogenies after removing divergent and ambiguously aligned blocks from protein sequence alignments. Syst. Biol. 56, 564\u2013577 (2007).","journal-title":"Syst. Biol."},{"key":"1313_CR64","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","volume":"25","author":"PJ Cock","year":"2009","unstructured":"Cock, P. J. et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25, 1422\u20131423 (2009).","journal-title":"Bioinformatics"},{"key":"1313_CR65","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312\u20131313 (2014).","journal-title":"Bioinformatics"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01313-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01313-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01313-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:53:16Z","timestamp":1670381596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01313-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-01313-5","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no personal competing interests. Allergan had no intervention in the experimental design and generation of results and\/or conclusions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"599"}}